(S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine: Your Key Pharmaceutical Intermediate Supplier in China

(S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine, a vital chiral building block with CAS number 147769-93-5, is essential for advanced pharmaceutical synthesis. As a leading manufacturer and supplier from China, we provide high-purity material critical for drug development and organic synthesis.

Get a Quote & Sample

Key Advantages of Sourcing Our Intermediate

Guaranteed Purity and Quality

We ensure that every batch of (S)-3-Methyl-1-(2-piperidin-1-ylphenyl)butylamine meets stringent quality control standards, providing ≥99% purity essential for pharmaceutical applications and accurate drug development.

Consistent Supply Chain

As a leading China manufacturer, we offer a stable and dependable supply of this vital pharmaceutical intermediate, helping you avoid production delays and maintain your R&D momentum. Contact us for current price information.

Expertise in Chiral Synthesis

Leverage our expertise in chiral chemistry. This compound is critical for chiral amine synthesis, enabling the development of stereospecific drugs and advanced organic compounds for pharmaceutical research.

Diverse Applications in Pharmaceutical Chemistry

Repaglinide Synthesis

This compound is a critical intermediate in the synthesis of Repaglinide, a widely used antidiabetic medication. Its precise chiral structure is vital for the efficacy of the final API.

Chiral Building Block

Its defined stereochemistry makes it an invaluable chiral building block for the synthesis of various complex organic molecules and other chiral amines in pharmaceutical R&D.

Neurological Disorder Drug Development

Research indicates potential applications in the development of pharmaceuticals for neurological disorders and mental health conditions due to its interaction with neurotransmitter receptors.

Organic Chemistry Research

Utilized in academic and industrial organic chemistry research for exploring new reaction pathways, synthetic strategies, and novel compound development.